Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma

BACKGROUND: Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired drug resistance. Therefore, elucidation of the molecular me...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Yoonhee, Koo, Harim, Yang, Yingxi, Shin, Sang, Zhu, Zhihan, Kim, Donggeon, Cho, Hee Jin, Mu, Quanhua, Choi, Seung Won, Sa, Jason K., Seo, Yun Jee, Kim, Yejin, Lee, Kyoungmin, Oh, Jeong-Woo, Kwon, Yong-Jun, Park, Woong-Yang, Kong, Doo-Sik, Seol, Ho Jun, Lee, Jung-Il, Park, Chul-Kee, Lee, Hye Won, Yoon, Yeup, Wang, Jiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010007/
https://www.ncbi.nlm.nih.gov/pubmed/36915208
http://dx.doi.org/10.1186/s13073-023-01165-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010007/
https://www.ncbi.nlm.nih.gov/pubmed/36915208
http://dx.doi.org/10.1186/s13073-023-01165-8

Ejemplares similares